Ardelyx
Buying intent
21 tracked signals | Top 14 topics are below | Marketing is carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Ardelyx's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
10d ago
11d ago
11d ago
10d ago
10d ago
11d ago
17d ago
17d ago
10d ago
13d ago
26d ago
11d ago
13d ago
10d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Ardelyx
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
Primary products / business lines
LinkedIn company profileArdelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and R
Top accounts researching Ardelyx
names withheld on the public pageThese are companies whose own people brought up Ardelyx unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
3,384 companies · 12,605 people are researching Healthcare Providers
Ardelyx's own team shows 4 signals on this topic. No one outside Ardelyx has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- CTV [Connected TV]296 cos · 655 people
- OTT Platforms217 cos · 572 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Marketing — 3 people; Leadership — 1 person
What's been said
public posts mentioning ArdelyxUp to 9 public excerpts naming Ardelyx from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.
A few months later, I'm still energized by the message Nicole Malachowski shared with the Ardelyx, Inc. Team at our National Meeting this past February...and that says everything. Her keynote on resilience, adaptability, leadership, and teamwork didn't just inspire in the moment; it sparked something that continues to grow across our organization. The conversations, the mindset shifts, the way people show up for one another...her words are still working. Two ideas in particular have taken root. The "wingman contract" — the commitment teammates make to build trust, communicate openly, and step up when it matters most — has given us a shared language for what great partnership looks like. And her concept of "harnessing headwinds" has genuinely changed how we approach challenges. Uncertainty is inevitable, but with the right mindset and the right people around you, those moments become fuel. We are so fortunate to do this work in life sciences, where every challenge we navigate and every team we strengthen has a real impact on patients' lives. Nicole's message reminded us of that purpose...and of how much more we're capable of together. Thank you, Nicole, for your generosity, your wisdom, and your belief in what teams can achieve. We're carrying it forward! 🙏
May 2026Today, we’ve announced an important leadership transition at Ardelyx: Felecia E. has joined the company as our new Chief Legal Officer. Felecia brings extensive experience in the biopharmaceutical industry, with deep expertise across legal, compliance, regulatory and government affairs. We’re excited to welcome her to Team Ardelyx, and look forward to the leadership and perspective she will bring as we continue to grow. At the same time, this is also a meaningful moment to recognize Elizabeth Grammer , who is retiring after an incredible 16 years at Ardelyx. I’ve had the privilege of working with Liz for many years, dating back to an earlier chapter in my career. Throughout that time, I’ve come to know her not only for her brilliance, but also for her deep care for the company, our employees and the patients we serve. As we built Ardelyx together, Liz was a trusted advisor to me – a steady hand, a thoughtful partner and an exceptional leader. One of the lessons from working with her that has stayed with me is to never forget to give people the opportunity to shine, to be supportive, to be direct and to always keep sight of why we do this work: to help patients. Liz, thank you for your partnership, your leadership, and your many contributions to Ardelyx. You have helped shape this company in lasting ways, and we are all better for it. We wish you all the best in your well-deserved retirement. Please join me in welcoming Felecia and congratulating Liz.
Apr 2026I'm hiring! The Scientific Communications team at Ardelyx is looking for an Associate Director, Medical Communications to help us deliver on our mission of improving the lives of patients. Know someone who'd be a great fit? Let's connect. #ArdelyxProud#Hiring https://lnkd.in/e5Wj5Vaw
Apr 2026Strategic priorities
Earnings call; SEC filingsAudit Data; Sales Revenue; Cash Flow; Financial Performance
What changed recently
Earnings call; SEC filingsAudit Data; Sales Revenue; Cash Flow; Financial Performance